Vilon

Vilon – Benefits & Side Effects

Vilon – Protocol

Vilon – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

Vilon – Identification

Common Names and Designations:

• Vilon (primary designation)

• Lysylglutamic acid (chemical nomenclature)

• Lys-Glu (amino acid shorthand)

• Lysyl-glutamic acid (alternative nomenclature)

• N-L-Lysyl-L-glutamic acid (IUPAC designation)

• H-Lys-Glu-OH (structural notation)

• Lysyl glutamate (alternative chemical name)

• KE (single-letter code in some literature)

• Peptide KE (designation in combination formulations)

CAS Number: 45234-02-4

Molecular Formula: C₁₁H₂₁N₃O₅

Molecular Weight: 275.3 Da (or 275.3 g/mol)

PubChem CID: 7010502

Origin and Classification:

• Source: Synthetic; derived from or modeled after natural thymic peptide sequences

• Biosynthesis: Chemically synthesized dipeptide; nonribosomal origin

• Functional Classification: Immunomodulatory bioregulator; tissue regeneration agent; chromatin-modulating peptide; aging-related bioregulator

• Structural Type: Linear dipeptide with standard peptide bond connecting lysine and glutamic acid residues

Amino Acid Sequence:

• Sequence (N-terminus to C-terminus): Lysine (Lys/K) - Glutamic acid (Glu/E)

• Sequence Length: 2 amino acids

• Single Letter Code: KE or LysGlu

• Structural Formula: H₂N-CH(CH₂CH₂CH₂CH₂NH₂)-CO-NH-CH(CH₂COOH)-COOH

Physicochemical Properties:

• Appearance: White to off-white crystalline powder

• Solubility: Highly soluble in aqueous solutions and standard biological buffers; compatible with physiological media

• Stability: Chemically stable at room temperature; resistant to standard storage conditions

• Storage: Stable at +5°C or lower when protected from light and moisture; lyophilized form commonly used

• pH Stability: Stable across physiological pH range (5-8)

• Melting Point: >200°C (with decomposition)

• Charge Profile: Contains one positively charged amino acid (lysine) and one negatively charged amino acid (glutamic acid), conferring near-neutral net charge at physiological pH

• Peptide Bond Type: Single standard peptide bond; susceptible to proteolytic degradation

• Isoelectric Point (pI): Approximately 7.0-7.5

Salt Forms and Formulations:

• Free base: H-Lys-Glu-OH

• Hydrochloride salt: Vilon·HCl

• Acetate salt: Vilon·CH₃COOH

• Lyophilized powder: Often supplied with mannitol as excipient

• Standard supply format: 20 mg lyophilized vials

Precursor and Related Molecules:

• Natural source: Derived from thymic peptide complex (Thymalin)

• Thymalin composition: Contains three peptide components: Thymalin (complex mixture), Crystagen, Thymogen, and Vilon

• Related Khavinson peptides: Epitalon (tetrapeptide from pineal gland), Livagen (peptide from liver), Cortagen (dipeptide from cortex)

Pharmacological Classification:

• Peptide bioregulator

• Immunomodulatory agent

• Chromatin-remodeling peptide

• Anti-aging bioregulator

• Tissue regeneration promoter

• Facultative heterochromatin activator

Regulatory Status:

• Not approved as pharmaceutical in United States or European Union

• Used as research peptide in preclinical and clinical research settings

• Approved in Russia and selected international markets as immunomodulatory agent

• Included in combination products marketed in various countries for immune support

Database Links and External References:

• PubChem: CID 7010502 - Complete chemical information, structure, and synonyms

• NCBI: Literature repository containing peer-reviewed studies on Vilon

• Chemical Suppliers: E-Peptide, BioLongevity Labs, Core Peptides, Raw Amino, Canlab International

• Khavinson Institute: Source research on peptide bioregulators and aging

Note: Vilon's extremely short 2-amino acid structure—making it one of the shortest documented peptides with demonstrated biological activity—distinguishes it from most other bioregulator peptides, which are typically longer chains. The balanced charge profile (one basic lysine residue, one acidic glutamic acid residue) contributes to its solubility and cellular compatibility. Vilon is frequently supplied as a component of multi-peptide complexes designed to target tissue-specific functions, appearing in formulations including Resiferin, Immunget, Nemores spray, and others.

Vilon – Research

Vilon is a super small peptide—just two building blocks of proteins—that acts like a coach for your body's cells, especially as you get older. It's from thymus gland studies (that's behind your chest where immune cells grow). Scientists check it for helping immune system fight better, slow aging in cells, and even protect against some sicknesses like kidney issues or cancers in animal tests. Used as shots in research, not pills.

Study: Vilon Helping Elderly Cancer Patients Live Longer

Benefits: Boosts survival after tough cancer treatments, cuts complications like infections, and improves daily life quality for older folks with gut cancers.

Link: https://pubmed.ncbi.nlm.nih.gov/16075684/

Summary: Doctors gave Vilon to old patients getting surgery, radiation, and chemo for rectal or colon cancer. Those getting it had way better 2-year survival, fewer repeat tumors, less spread, and quicker bounce-back. No big side effects. It's like giving the body extra strength to heal and fight after hard hits. Quality of life went up—they felt stronger, less tired. This shows Vilon as a helper drug for cancer care in seniors where normal treatments wear them out.

Study: Vilon Fixing Kidney Problems Early On

Benefits: Lowers bad proteins in blood that harm kidneys and fixes leaky small blood tubes, helping early chronic kidney disease stay under control.

Link: https://pubmed.ncbi.nlm.nih.gov/16142267/

Summary: Rats with starting kidney failure got Vilon shots. Two months in, their blood had less transforming growth factor (a troublemaker making scars), and gut blood vessels stopped leaking fluids. This kept kidneys working better longer. By months 4-6, effects faded, so best early. Vilon balances body fluids and stops damage spread, like patching leaks before flood. Promising for human kidney protection without strong meds.

Study: Vilon Slowing Bladder Cancer Growth in Animals

Benefits: Cuts new cancer starts by half, lowers pre-cancer spots, great for preventing urinary tract tumors.

Link: https://pubmed.ncbi.nlm.nih.gov/11586406/

Summary: Rats fed cancer-causing stuff got Vilon. Only 56% grew bladder tumors vs 75% without. Early bad changes dropped a lot too. Vilon stopped cancer from taking hold by tweaking cell growth signals. Twice less serious tumors formed. This hints it's a blocker for chemicals turning normal cells wild. Safe in tests, could pair with checkups for high-risk people. Like a shield for bladder lining.

Study: Vilon Boosting Cell Youth and Fighting Tumors

Benefits: Kills more tumor cells, slows growth via better cell death, helps old rats fight transplanted cancers.

Link: https://pubmed.ncbi.nlm.nih.gov/15490736/

Summary: Old rats with planted sarcoma tumors got tiny Vilon doses. Tumor cells died more (apoptosis up), growth slowed, some tumors got bloody and shrank. Vilon changed blood vessel growth around tumors, starving them. Better than controls. Also, another peptide Epithalamin did similar. Shows Vilon tweaks tumor neighborhood to fight back. Hope for cancer add-on therapy, especially in aging bodies where immunity dips.

Vilon research focuses on anti-aging and immune perks, strong in animal and small human tests from Russian labs. It nudges genes for repair, fights inflammation, protects organs. Not FDA-approved yet—research only. Benefits shine for longevity, cancer aid, kidney health.

Vilon – Research Links